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The term human T  cell leukemia/lymphoma virus (HTLV) denotes a unique 
family  of  T  cell  tropic  human  type  C  retroviruses  (1,  2). 1 We  studied  the 
generation of cytotoxic T  lymphocytes (CTL) derived from a  patient who had 
an  unusually  long  survival  after  therapy for an  HTLV-associated  T  cell  iym- 
phoma.  The  purpose  of this  paper  is  to  report  the  characteristics  of a  T  cell 
growth factor-dependent line of CTL from this patient which lyses autologous 
tumor cells infected with HTLV. The data suggest a  form of cytotoxic activity 
restricted by products of the major histocompatibility complex (MHC). 
Materials and Methods 
The Patient.  MJ is a 53-yr-old white male who has circulating antibodies against internal 
structural proteins of HTLV.  In  1977,  he  was  diagnosed as having cutaneous T  cell 
lymphoma, and he eventually became a complete responder to a regimen of  chemotherapy, 
whole-body electron beam irradiation, and topical nitrogen mustard. The patient's disease 
was in clinical remission when these studies were initiated in January 1983. 
Target Cells.  MJ  tumor is an  HTLV-producing neoplastic T  cell line derived from 
patient MJ and now propagated in the absence of exogenous T  cell growth factor. HUT- 
102-B2 and WA tumor are HTLV-producing T  cell lines derived from CR and WA, 
patients who had T  cell lymphomas and evidence of infection with HTLV in vivo. MJ-B 
and CR-B are Epstein-Barr virus (EBV)-transformed B cell lines derived from patients MJ 
and CR,  respectively. CI/MJ and C5/MJ  are cell lines that resulted from the in vitro 
infection of two unrelated normal human cord cell populations using HTLV from the 
index patient  MJ.  C91/PL  is  a  cell  line  that  resulted  from the  in  vitro infection of 
unrelated normal human cord cells with HTLV derived from PL, another HTLV-infected 
patient who had a T cell lymphoma. Other cell lines used included Molt 4, a long-term T 
cell line; Daudi, an EBV-transformed B cell line; K562, an erythroid line; Chang, a human 
hepatoma cell line; and NS-I, a mouse plasma cell line. We also used EBV-transformed B 
cell lines, GT-B and MM-B,  derived from normal individuals who were partially HLA- 
matched with the index patient, MJ. 
Cell Separation and Generation of CTL in Long-term Culture.  Peripheral blood mononu- 
i The strains of HTLV studied in this report belong to the subgroup HTLV-I. 
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clear  cells  (PBM)  were  prepared  from  heparinized blood  of patient  MJ  and  normal 
individuals by Ficoll-Isopaque gradient centrifugation. Aliquots of PBM (107 cells) from 
patient MJ or a normal individual were co-cultured with 108 irradiated (12,000 rad) MJ 
tumor cells in upright flasks (3050; Costar, Cambridge, MA) at 37 °C in 5% CO2-containing 
humidified air in I0 ml of RPMI  1640 supplemented with 10% heat-inactivated human 
AB serum, 4 mM L-glutamine, 5 X 10 -5 M 2-mercaptoethanol, 50 U/ml penicillin, and 
50 ~g/ml streptomycin. After day 6, these cultured cells were continuously exposed to 
20%  lectin-depleted T  cell growth factor (ld-TCGF) containing RPMI  1640 with 10% 
heat-inactivated fetal calf serum (FCS) without further use of human serum. The cultures 
were repeatedly stimulated with irradiated MJ tumor cells at 7-14-d intervals. 
Cytotoxicity Assay.  A 4-h 5~Cr-release assay was carried out in round-bottomed microtiter 
plates (Linbro Chemical Co., Hamden, CT). 10,000 5~Cr-labeled target cells were mixed 
with various numbers of effector cells in 150 #1 RPMI 1640 supplemented with 4% FCS. 
After the plates were incubated for 4 h at 37°C in 5% COs-containing humidified air, 
supernatants were harvested with the Titertek Supernatant Collection System and meas- 
ured  for  radioactivity.  The  percentage  specific  5~Cr release  was  determined  by  the 
following formula: 100  x  [(release  in test -  spontaneous release)/(maximum release - 
spontaneous release)].  Spontaneous release was always <20% of maximum release for all 
target cells. 
Competitive Cold-Target Inhibition Assays.  The effectors were dispersed in 100 ~1 RPMI 
1640 supplemented with 4%  FCS and various numbers of unlabeled target cells were 
added in 50 ~1 medium. Then ~'Cr-labeled MJ tumor cells (104 cells/well) were added in 
50 #1 of medium. The ratios of effector/labeled target cells were 5:1 or 10:1. The plates 
were then incubated and processed using the usual cytotoxic assay to determine specific 
5~Cr release. 
Analysis of Surface Antigens by Monoclonal Antibodies.  The reactivity of cells with OKT3, 
OKT4,  OKT8  (Ortho  Diagnostic  Systems  Inc.,  Westwood,  MA),  HLA-DR  (Becton, 
Dickinson & Co., Sunnyvale, CA), and anti-Tac (3) monoclonal antibodies was determined 
by indirect immunofluorescent microscopy or by fluorescence-activated cell sorter analysis 
(BD FACS Systems, Sunnyvale, CA). 
Results 
Generation of a Specific CTL Line from the Patient.  Fresh PBM from patient MJ 
did not mediate specific cytotoxicity (data not shown).  However, on day 20 of 
culture  the  patient's  cells  mediated  a  substantial  level  of specific cytotoxicity 
against  MJ  tumor  cells  (Fig.  1A-l).  By  contrast,  a  normal  individual's  PBM 
exposed  to  MJ  tumor  cells  and  cultured  under  the  same  conditions did  not 
mediate specific cytotoxicity and killed a variety of target cells (Fig.  1 B). 
After repeated cycles of stimulation with MJ tumor cells and expansion with 
/d-TCGF, the cytotoxicity of the cultured cells from the patient against various 
tumor targets other than his autologous tumor cells was progressively reduced. 
On day 27 and beyond, the patient's cultured cells were cytotoxic specifically for 
his  own  tumor  cells  in  effector/target  ratios  of 5:1  or  less  compared  with  a 
variety of unrelated HTLV-infected and uninfected target cells (Fig.  1 A-2 and 
A-3). The specificity was confirmed by competitive cold-target inhibition studies, 
which showed a linear inhibition of cytotoxic effector activity by the addition of 
unlabeled MJ tumor cells (Fig. 2). The CTL line has now been maintained for 
>150 d. 
Almost all cells in the CTL line after 22 d in culture reacted with OKT3 (96- 
100%) and OKT8 (98-100%) antibodies; 43 and 92% reacted with anti-Tac and 
HLA-DR antibodies, respectively. There were <3%  OKT4 reactive cells. How- 996  MITSUYA  ET  AL.  BRIEF  DEFINITIVE  REPORT 
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FXGURE  1.  Generation of a  CTL line (MJ CTL) reactive with autologous HTLV-infected 
tumor cells.  MJ CTL were generated by co-culturing 107 PBL from the patient MJ with 10 ~ 
irradiated MJ tumor cells in vitro. On day 6, these cells were exposed to ld-TCGF. PBM from 
a normal individual were treated in the same manner. MJ CTL were tested on day 20 (A-I), 
day  27  (A-2), and day  47 (A-3).  Comparably cultured cells from a  normal individual were 
tested on day 21  (B).  Target cells:  MJ tumor (O),  HUT-102-B2 (A),  CR-B (A), Chang (1"1), 
Molt4 (11), K562 (~7), Daudi (,), NS-I (O), WA tumor (O), CI/MJ (~), C5/MJ (<>), and C91/ 
PL (.). Cytotoxicity was measured in a 4-h ~lCr-release assay.  The specificity of the cytotoxic 
activity progressively increased with time in culture. 
ever, in the MJ tumor cell population, we observed a different phenotypic profile: 
0-17% of the cells were reactive with OKT3, 61-68% were reactive with OKT4, 
and <1% were reactive with OKT8. 
HLA Restriction of Cytotoxic Activity.  The specific T  cell-mediated lysis of virally 
infected target cells requires an associative recognition of MHC-encoded antigens 
in a  variety of settings (4).  Consequently, we tested the CTL from patient MJ 
(MJ CTL), MJ tumor, and various cell lines for expression of HLA alloantigens 
(Table I) using the microcytoxicity technique (5). 
MJ CTL failed to kill various HTLV-infected target cells that did not share 
HLA antigens expressed by MJ CTL. However, they were cytotoxic against MJ 
tumor cells and WA tumor cells, which did share A1, B8, Cw7, and DR3 (Fig. 
1 A-3), suggesting an HLA-restricted form ofcytotoxicity. To confirm and extend 
these observations, cold-target competition assays were performed (Fig. 2B and 
C).  The  cytotoxic activity  of MJ  CTL  against  MJ  tumor cells  was  selectively 
blocked  by  unlabeled  MJ  and  WA  tumor  cells  but  not  by  any  other  HLA- 
unmatched cells tested. 
To further characterize the specificity of MJ'CTL, we tested EBV-transformed 
cells from normal individuals who shared A 1, B8, and DR antigens with patient 
MJ.  Moreover,  we  tested  an  EBV-transformed  line  derived  from  the  index 
patient himself. MJ CTL did not kill these various HLA-matched control target 
cells (Table II). The cytotoxicity of MJ CTL against autologous MJ tumor cells 
was not inhibited by the partially HLA-matched MM-B and GT-B cells as cold 
targets (Fig. 2 C). These data suggest that the cytotoxicity of MJ CTL is directed 
against  HTLV-related  antigen(s)  and  that  HTLV-specific  cytolytic activity  is 
restricted by products linked to the MHC. 70 
60 
5O 
< 
ILl 
~.  3O 
a. 
oo  2O 
10 
MITSUYA  ET  AL. 
A. 
-  A 
\~.  \ 
20 
10 
0  0 
I  I  l  1  I 
1:1 1:2  1:51:10  1:50 
BRIEF  DEFINITIVE  REPORT 
C. 
90 
80 
•  '\"  70 
6O 
,,  "O  50 
4O 
3O 
20 
10 
--  0 
I  I  I  1  I 
1:1 1:2  1:5 1:10  1:50 
..... 
I  I  I  I  T 
1:1 1:2  1:5 1:10  1:50 
RATIO LABELED/COLD  TARGETS 
FIGURE 2.  Competitive cold-target inhibition of MJ CTL activity. In these studies,  labeled 
MJ tumor cells were used as targets in the presence or absence (O) of various competitive cold- 
target cells.  The effector/labeled target cells ratios were 5:1, 5:1, and  10:1  in A, B, and C, 
respectively. Cold-target cells: MJ tumor (O),  HUT-102-B2 (A),  K562  (V),  Daudi (V),  WA- 
tumor  (O),  CI/MJ  (~),  C5/MJ  (<>), C91/PL  (O),  GT-B  (6~), and  MM-B  (~).  The  values 
represent the mean percentage specific 51Cr release in a  4-h assay  done in triplicate. MJ or 
WA  tumor  cells (known  to  share  certain  histocompatibility  antigens)  could  competitively 
inhibit the cytotoxic activity. 
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Discussion 
This initial characterization of a cytotoxic T  cell response to a  human retro- 
virus-associated tumor establishes a parallel with the well-studied animal models 
of immune responses to retrovirus-induced tumors (6).  This is of interest from 
several perspectives.  The first  involves the relationship between cell-mediated 
immunity to type C retroviruses and leukemogenesis. There are data suggesting 
that chronic immunostimulation and the profound general amplification of the 
immune system resulting  from persistent  viremia  eventually leads  to  somatic 
errors, bringing about a neoplastic transformation of proliferating T  cells (7). 
In a related point of view, T  cells "transformed" by retroviruses might repre- 
sent precisely those lymphocytes whose antigen specificity is directed against viral 
determinants  (receptor-mediated  leukemogenesis theory)  (8),  and  continuous 
exposure to the stimulating antigen  would be necessary in maintaining the T 
cell-transformed  state.  The  receptor-mediated  leukemogenesis theory  per  se 
requires no event beyond the development of the matching receptor and ligand 
in an appropriate microenvironment. Accordingly, in certain settings, suscepti- 
bility  to  viral  leukemogenesis could paradoxically  correlate  with  various  cell- 
mediated immune responses (including the generation of cytotoxic T  cells).  If 
this hypothesis is correct, the induction of immune tolerance to virus-associated 
antigen(s) would decrease the likelihood of vitally induced transformation. 998  MITSUYA  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE  I 
The HLA-Phenotype* of Cells  from Patient MJ and HTLV-infected Target Cells 
Cells  HLA-A  HLA-B  HLA-C  HLA-DR 
MJ PBM*  A1  B8, B27  Cw6, Cw7  DR3,  DR7 
MJ CTL  A1  B8, B27  Cw6, Cw7  DR3,  DR7 
MJ Tumor  A1  B8, B27 (B17)  Cw6, Cw7  DR3,  DR7 
WA Tumor  A1, Aw24 (A11)  B8, Bw22 (B15)  Cw3, Cw7  DR3 
HUT-102-B2  Aw30, Aw31 (A10) (A11) (A29)  BI7, B18 (Bw35) (BwS0)  DR2, DRw6 
(m2) 
CI/MJ  A10, A29  B12, Bw35 (Bw53)  Cwl  DR2 
C5/MJ  Aw32 (Aw30)  B5, Bw35 (Bw21)  Cw4  DR2 
C91/PL  A3  Bw51, Bw52  Cw4, Cw6  DR2,  DR4 
GT-B  !  A 1, A3  B8  Cw7  DR3 
MM-B  !  A1, A3  B8, Bw35  Cw4, Cw6  DR3,  DR7 
* It has been previously noted that cells infected with HTLV appear to frequently express extra (alien) class  I 
histocompatibility  antigens (2,  12) When appropriate uninfected control cells from the same individuals were 
available  for HLA typing, alien histocompatibility  markers are listed in parentheses. 
* Freshly harvested PBM cells from patient MJ. 
| EBV-infected B cells obtained from normal control individuals. 
TABLE  II 
Lack of Cytotoxicity of  MJ CTL Against Autologous and Partially HLA-matched EBV-transformed B 
Cell Line Targets 
Target cells 
Effectors  MJ tumor  MJ-B  GT-B  MM-B 
10:1"  1:1  10:1  1:1  10:1  1:1  10:1  1:1 
MJ CTL*  63.8 ±  3.0  t  24,6 ±  5.2  6.3 3= 1.8  5.3 3= 1.3  -4,5 ±  0,1  -10.7 3= 1.9  -1.9 ±  0.3  -1.3 ± 0.8 
TOCTL  I  36.2±4.2  17.9±4.1  22.73=6.0  15.9±2.7  29.9±1.3  8.7±2.4 
MICTL  !  20.3±2.9  4.4± 1.5  9.9±2.4  0.4± 1.2 
* Effector/target ratio. 
* MJ CTL were tested on day 51 of culture. 
0 All determinations were made in triplicate  and data are expressed as the mean ±  1 SD. 
! TO CTL and MI CTL were derived from normal individuals'  PBM, continuously exposed to ld-TCGF for 14 and 52 d, 
respectively,  after stimulation with irradiated WA tumor and irradiated MJ tumor cells, respectively. 
An additional perspective from which the current results may be viewed relates 
to the role of the host ceil-mediated immune response in the control of tumor 
growth. Several studies have shown that the emergence of specific cell-mediated 
immunity in the context of a regressing tumor confers resistance to subsequent 
challenge with the same tumor (9).  Such immunity results from the generation 
of regulatory and  cytotoxic effector T  cell  responder  populations,  and  this 
immunity can be adoptively transferred to unimmunized syngeneic hosts. 
Of perhaps greater clinical relevance are reports involving murine models of 
adoptive immunotherapy or chemoimmunotherapy in which fresh or cultured 
immune  T  cells  specific  for  retrovirus-induced  tumors  were  able  to  effect 
complete tumor  regression  upon  transfer to  syngeneic hosts already bearing 
otherwise lethal, disseminated tumors (10, 11). The potential clinical applications 
of cytotoxic T  cells propagated in vitro are topics for future research. 
Summary 
Lymphocytes from a patient who had an unusually long survival after therapy 
for a  human T  cell leukemia/lymphoma virus (HTLV)-associated T  cell lym- 
phoma  were stimulated in  vitro  with an  autoiogous tumor  cell  line,  and  the MITSUYA  ET  AL.  BRIEF  DEFINITIVE  REPORT  999 
generation of cytotoxic T  lymphocytes (CTL) was studied. CTL generated were 
directed  against  autologous  HTLV-associated  tumor  cells.  These  propagated 
CTL  were  OKT3+,  OKT4-,  and  OKT8+.  The  cytotoxic activity required 
target tumor cells that were infected with HTLV and also expressed histocom- 
patibility antigens in common with the patient, suggesting a  major histocompat- 
ibility complex-restricted associative recognition of target antigens expressed on 
the tumor cell membrane. 
Received for publication 21 April 1983 and in revised  form 21 June 1983. 
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